Active substance combination for the treatment of diabetes
申请人:Laboratorios del Dr. Esteve S.A.
公开号:EP1946778A1
公开(公告)日:2008-07-23
The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.
4-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments
申请人:TORRENS Antoni
公开号:US20070073056A1
公开(公告)日:2007-03-29
The present invention relates to 4-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
[EN] 4,5-DIHYDR0-1H-PYRAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS<br/>[FR] DERIVES DE 4, 5-DIHYDR0-1H-PYRAZOLE, PREPARATION ET UTILISATION DE CEUX-CI COMME MEDICAMENTS
申请人:ESTEVE LABOR DR
公开号:WO2007009689A1
公开(公告)日:2007-01-25
[EN] The present invention relates to 4-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. [FR] L'invention concerne des composés de pyrazoline 4 substituée de formule I, des procédés de préparation de ceux-ci, des médicaments comprenant ces composés, ainsi que l'utilisation de ceux-ci dans la préparation d'un médicament destiné au traitement d'êtres humains et d'animaux.
Substituted pyrazoline for preventing weight gain
申请人:Laboratorios del Dr. Esteve S.A.
公开号:EP1946777A1
公开(公告)日:2008-07-23
The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.